VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - March 2, 2006) - Inflazyme Pharmaceuticals Ltd. (TSX:IZP) together with Helicon Therapeutics, Inc. of New York, today announced the initiation of a Phase IIa clinical study with the PDE4 inhibitor, IPL455,903 (also known as HT-0712) in subjects with Age Associated Memory Impairment. IPL455,903 is a PDE4 inhibitor licensed to Helicon Therapeutics that has shown to be safe, well tolerated and non-emetic in healthy volunteers in single and multi-dose studies conducted to date.
